Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
PaperCitations, authors & open-access status
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 957 citations, 2012 year and closed oa status.
957
Citations
2012
Year
closed
OA Status